Trial Profile
Phase I study of PS-341 [bortezomib] in acute myeloid leukemias myelodysplastic syndromes and chronic myeloid leukemia in blast phase
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 27 Sep 2005 New trial record.